According to a new analysis from Datamonitor Healthcare, the volume of deals in the CNS space has fallen since 2012 but the overall value of alliances is increasing, particularly when it comes to up-front payments for potential Alzheimer's therapies.

Data from two studies in obstructive sleep apnea suggest drug may hold its own against approved generics, analysts say.

Even Series A rounds have been large during recent record-breaking years for biotech venture capital investment, but it looks like smaller financings for early-stage companies may be in the midst of a comeback. With VC firms closing new funds, that raises the question: Will the number of preclinical and Phase I financings increase?

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced July-August 2015.